In 1997, James Liao, multimillionaire general manager of ADI Corporation, purchased the operating rights for Adimmune in 2001 for NT $ 200 million with the help of public shares from the National Development Fund. After that, Adimmune became more aggressive in its upgrading efforts, sending employees on an annual basis to the Kitasato Institute to study the vaccine manufacturing process based on fertilized chicken eggs.
1997 年，當時身價百億的誠洲電子老闆廖繼誠，以台幣 2 億元買下國光經營權，並於 2001 年獲得行政院國家發展基金官股入股；此後國光升級轉型之路更積極，幾乎每年都派員到北里，實地學習雞胚胎蛋疫苗的生產製程。